Kyinno Biotechnology is a preclinical contract research operation (CRO) dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery.

Our strength is the strong R&D team with decades of experience in the pharmaceutical and biotechnology industry in the United States. We have comprehensive development capability to construct stable cell lines engineered in unique and new targets through CRISPR Knock-in/Knock-out technology. Our animal facilities with a capacity of 1,000 cages (5,000 mice)are located in Beijing. We can perform 60 projects at the same time.

Our service platforms include:

1. Off-the-shelf stable cell lines
More than 3000 engineered cell lines are available (in stock) in our Waltham logistic center (MA, United States). The lead time
will be 2~3 business days in the United States and about 2 weeks in Europe.
2. Custom cell line engineering
Background cell lines. Over 700 human tumor cells and other animal cells are available for engineering.
Technology.
CRISPR Knock-in/Knock-out technology (homozygous clone and heterozygous clone) for site-specific
integration.
Overexpress gene/target using lentivirus vector transfection
Standard deliver pool/single clone with validated PCR sequencing/Mycoplasma free/STR/HiBit test/Western Blot (WB)
validation/siRNA test.

2. Cell-based assay validation and drug screening(small molecule compound and PROTACs)

Cell proliferation assay(cell cytotoxicity assay).3D cell proliferation assay and 2D cell proliferation assay FACS binding assay/FACS internalization assay/ Immunol pathway assay/ ELISA assay ADCC cell-based bioassays/antibody-dependent cellular phagocytosis (ADCP) assays

3. Drug combination (in vivo combination and in vitro combination) integrated with bioinformatics analysis.

4. Pharmacology in vitro and in vivo study service, PK/PD efficacy studies in our ideal immunodeficient models.
Hundreds of cell line-derived xenograft (CDX) mouse models are validated and are ready to test new anti-cancer drugs.
BaF3 xenograft models
Syngeneic models
PBMC humanized mouse model
Luciferase tumor model
IVIS Imaging/Whole blood, spleen, and lymph node analysis/Chemotherapy validation

4. Phage display library and hybridoma technology for antibody drug discovery
Humanization and affinity maturation
Draggability and immunogenicity evaluation
Nanobody
Hybridoma services
Single B cell sequencing
5. Common light chain technology
6. Cancer cell panel compound profiling and biomarker discovery
7. Mega screening platform
HRD Homologous recombination deficiency (HRD) score of the cell lines was calculated and 100 cell lines with high HRD scores
were selected for compound screening.

Kinase BaF3 cell panel screening. With our gene-editing expertise, KYINNO has constructed over 700 BaF3 cell lines which harbor various hotspot kinase drug targets. Our dedicated cell-based assay team daily handles hundreds of BaF3 cell lines and thousands of test articles. Most of the engineered BaF3 cell lines are suitable for in vivo efficacy studies. By in vitro screening, the compounds showing good potency can be quickly selected for further in vivo efficacy study without any delay in our one-stop service. Target: EGFR family, VEGFR family, FGFR family, EML4, ALK, NTRK family, FLT3 family, ROS1, HER2, HER3, BCR-ABL, cKit, RET, TAM family, KRAS, NRAS, HRAS, IGF1R, TPR-Met, etc. Innovative membrane proteins screening array MPSA-AB5000 The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to human membrane proteins for determining the specificity and preclinical safety of antibodies, CAR-T cell therapies, ADC, and other biotherapeutics. Here are some key features and benefits of AB5000: Unparalleled Antibody Specificity Screening. Our advanced platform allows for screening a wide range of human membrane proteins, which are critical for accurate specificity assessment. Early Off-Target Screening. The largest collection of human membrane proteins is natively expressed in live cells. You can conveniently determine the specificity and preclinical safety of biotherapeutics. Rapid, Simple, and Highly Sensitive. This cutting-edge technology provides rapid, simple, and highly sensitive results by measuring binding through ADCC via a luciferase reporter cell line. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Comprehensive Preclinical Safety Assessment.

Our products catalogs:
Kinase cell line
Immune molecule cell line
Gene Editing Cell line
Engineered reporter cell lines
Luciferase cell line
Fluorescence-labeled cell line
Drug-resistant cell line

Antibody and proteins with fully validated functions in reporter cell lines
Isotype control
Therapeutic antibody
Hybridoma
Recombinant protein